ARTICLES BY LOUIS

• Your CDMO And Your Glass Vials: Best Practices For Development

  Today the mention of “vials” leads to questions of supplies for COVID-19 vaccines. But thoughts of vials normally pertain to your own drug develop program needs. For advice, I asked one of the biggest glass producers in the world.

• But Where In The U.S.? Puerto Rico In The Reshoring Race

  We are refocused on drug development and manufacture in the U.S. But where in this big country makes the most dollars and sense for locating operations? One place drug manufacturing has traditionally flourished is Puerto Rico.

• “We Forgot Our People”: The Time Outsourcing Might Have Stopped

  “But we forgot our people,” says an introspective biopharma executive, regarding pre-coronavirus risk assessments. Here's a look at what did and might have happened, and thoughts for the future of outsourcing.

• Non-CDMOs Serving Cell And Gene Therapy Developers

  There's a new cell-and-gene service organization out there: the non-CDMO. Here's who they are, an analysis of why they're different, and a look at how they can help you.

• Roadmap To U.S. Drug Manufacturing: Outsource And Build At Home

  Nexus Pharmaceuticals has laid out a roadmap - and is living proof - we can develop and manufacture even generics in the U.S. And that goes for both in-house and at CMOs. 

• New Jersey Solutions For Cell And Gene Development and Manufacturing

  New Jersey’s first university-based, cell-and-gene-therapy development and manufacturing innovation center for-hire, was founded on solving three critical industry needs.

• Drug Tariffing: How Trade Policy And Politics Manipulate Your Outsourcing

  Tariffs, historic trade policy, politics: Most likely not top-of-mind right now. Here’s why they should be, particularly for younger professionals at U.S. biotechs leveraging CDMOs.

• The Oral Solid Dose Path To U.S. Partnerships

  OSD drugs are receiving the benefits of new technologies, formulation ideas, and other processing innovations. Can innovation pare COGs to open up more production in the U.S.? Here's our assessment.

• Common Drugs Now Made In America!

  It begins in a typical flash hurled by our hyrdoxycloriquine President. A U.S. drug manufacturer gets up to $812 million in federal funding for advanced manufacturing of America's most essential medicines. More politics or real progress?

• Circle Economics And A Man Made In America

  Inspiration and "circle economics" could help shape your outsourcing decisions. And who knows: It all might end up supporting a more robust national drug-manufacturing infrastructure.